BACKGROUND: Macitentan is a clinically approved endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH). Increasing use of combination drug therapy in PAH means that it is important to recognize potential drug-drug interactions (DDIs) that could affect the efficacy and safety of macitentan in patients with PAH. OBJECTIVE: Two Phase 1 studies were conducted to investigate the effect of macitentan at steady-state on the pharmacokinetics of the breast cancer resistance protein (BCRP) substrates, rosuvastatin and riociguat in healthy male subjects. Another objective was to determine the safety and tolerability of concomitant administration of rosuvastatin or riociguat with macitentan. METHODS: Healthy male subjects received a single oral dose of rosuvastatin 10 mg (n = 20) or riociguat 1 mg (n = 20) on Day 1 (reference treatment). A loading oral dose of macitentan 30 mg was administered on Day 5 followed by macitentan 10 mg once-daily from Day 6 to Day 15 (riociguat study) or Day 6 to Day 16 (rosuvastatin study). A concomitant oral dose of rosuvastatin 10 mg or riociguat 1 mg was administered on Day 10 (test treatment). Pharmacokinetics were evaluated for 96 h after treatment on Day 1 and for 144 h (riociguat study) or 168 h (rosuvastatin study) after treatment on Day 10. To compare the reference and test treatments, the geometric mean ratio was calculated for the maximum plasma concentration (Cmax), the area under the plasma concentration-time curve (AUC) from zero (pre-dose) to time of the last measured concentration above the limit of quantification (AUC0-t), the AUC from zero to infinity (AUC0-∞) and the terminal elimination half-life (t½) of rosuvastatin, riociguat and riociguat's metabolite, M1. The difference in the time to reach maximum plasma concentration (tmax) was determined by the Wilcoxon test. Trough levels of macitentan and its metabolite, ACT-132577, were measured and safety was monitored throughout. RESULTS: Ninety percent confidence intervals of the geometric mean ratios were within the bioequivalence criteria of 0.80-1.25. There was no significant difference between test and reference tmax. Rosuvastatin or riociguat did not affect the steady-state concentrations of macitentan and ACT-132577. The adverse event profile was consistent with the known safety profiles of the drugs. CONCLUSIONS: Macitentan 10 mg did not affect the pharmacokinetics of BCRP substrates, rosuvastatin or riociguat in healthy male subjects. EudraCT numbers: 2017-003095-31 and 2017-003502-41.

Actelion Pharmaceuticals Ltd Gewerbestrasse 16 4123 Allschwil Switzerland

Aixial s r o Brno Czech Republic

Clinical Research Services Mannheim GmbH Mannheim Germany

Idorsia Pharmaceuticals Ltd Allschwil Switzerland

Janssen Global Clinical Pharmacology Turnhoutseweg Beerse Belgium

Zobrazit více v PubMed

Lai YC, Potoka KC, Champion HC, et al. Pulmonary arterial hypertension: the clinical syndrome. Circ Res. 2014;115(1):115–130. doi: 10.1161/CIRCRESAHA.115.301146. PubMed DOI PMC

Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328(24):1732–1739. doi: 10.1056/NEJM199306173282402. PubMed DOI

Rubens C, Ewert R, Halank M, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest. 2001;120(5):1562–1569. doi: 10.1378/chest.120.5.1562. PubMed DOI

Chester AH, Yacoub MH. The role of endothelin-1 in pulmonary arterial hypertension. Glob Cardiol Sci Pract. 2014;2014(2):62–78. PubMed PMC

Arai H, Hori S, Aramori I, et al. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990;348(6303):730–732. doi: 10.1038/348730a0. PubMed DOI

Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990;348(6303):732–735. doi: 10.1038/348732a0. PubMed DOI

Lajoie AC, Bonnet S, Provencher S. Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges. Pulmon Circ. 2017;7(2):312–325. doi: 10.1177/2045893217710639. PubMed DOI PMC

McGoon MD, Miller DP. REVEAL: a contemporary US pulmonary arterial hypertension registry. Eur Respir Rev. 2012;21(123):8–18. doi: 10.1183/09059180.00008211. PubMed DOI PMC

Monaco TJ, Davila CD. Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension. Drug Des Dev Ther. 2016;10:1675–1682. PubMed PMC

Gatfield J, Mueller Grandjean C, Sasse T, et al. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One. 2012;7(10):e47662. doi: 10.1371/journal.pone.0047662. PubMed DOI PMC

Sidharta PN, Treiber A, Dingemanse J. Clinical pharmacokinetics and pharmacodynamics of the endothelian receptor antagonist macitentan. Clin Pharmacokinet. 2015;54:457–471. doi: 10.1007/s40262-015-0255-5. PubMed DOI PMC

Summary of product characteristics . Opsumit® (macitentan) 10 mg tablets, for oral use. London: Actelion Registration, Ltd.; 2018.

Elsby R, Hilgendorf C, Fenner K. Understanding the critical disposition pathways of statins to assess drug–drug interaction risk during drug development: it’s not just about OATP1B1. Clin Pharmacol Ther. 2012;92(5):584–598. doi: 10.1038/clpt.2012.163. PubMed DOI

Frey R, Becker C, Saleh S, et al. Clinical pharmacokinetic and pharmacodynamic profile of riociguat. Clin Pharmacokinet. 2018;57(6):647–661. doi: 10.1007/s40262-017-0604-7. PubMed DOI PMC

Khaybullina D, Patel A, Zerilli T. Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P T. 2014;39(11):749–758. PubMed PMC

Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol. 2007;99(3):410–414. doi: 10.1016/j.amjcard.2006.08.051. PubMed DOI PMC

Crestor [10 mg film-coated tablets summary of product characteristics]. Bedfordshire, UK: AstraZeneca UK. 2018. https://www.medicines.org.uk/emc/product/7559/smpc. Accessed 04 Feb 2019.

Adempas [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc. 2018. http://labeling.bayerhealthcare.com/html/products/pi/Adempas_PI.pdf. Accessed 04 Feb 2019.

Borkowski L, Steigerwald K. Validation of determination of rosuvastatin in plasma samples of subjects. ACC GmbH Analytical Clinical Concepts, Schöntalweg 9, 63849 Leidersbach, Germany. 2017.

Borkowski L, Steigerwald K. Validation of quantitative determination of the concentration of riociguat and its metabolite desmethyl-riociguat in plasma samples of subjects. ACC GmbH Analytical Clinical Concepts, Schöntalweg 9, 63849 Leidersbach, Germany. 2018.

Zimmermann T. Validation of an analytical method for the determination of ACT-064992 and its metabolite ACT-132577 in human plasma samples by LC-MS/MS. Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, 4123 Allschwil, Switzerland. 2014.

Steurer A. Supplementary validation of an analytical method for the determination of ACT-064992 and its metabolite ACT-132577 in human plasma samples by LC-MS/MS. Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, 4123 Allschwil, Switzerland. 2016.

Martin P, Gillen M, Ritter J, et al. Effects of fostamatinib on the pharmacokinetics of oral contraceptive, warfarin, and the statins rosuvastatin and simvastatin: results from phase I clinical studies. Drugs R D. 2016;16(1):93–107. doi: 10.1007/s40268-015-0120-x. PubMed DOI PMC

Frey R, Reber M, Krätzschmar J, et al. Riociguat (BAY 63-2521) and aspirin: a randomized, pharmacodynamic, and pharmacokinetic interaction study. Pulm Circ. 2016;6(Suppl 1):S35–S42. doi: 10.1086/685014. PubMed DOI PMC

Martin PD, Warwick MJ, Dane AL, et al. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. Clin Ther. 2003;25(8):2215–2224. doi: 10.1016/S0149-2918(03)80214-X. PubMed DOI

Birmingham BK, Bujac SR, Elsby R, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. Eur J Clin Pharmacol. 2015;71(3):329–340. doi: 10.1007/s00228-014-1800-0. PubMed DOI

Becker C, Frey R, Unger S, et al. Pharmacokinetic interaction of riociguat with ketoconazole, clarithromycin, and midazolam. Pulm Circ. 2016;6(Suppl 1):S49–S57. doi: 10.1086/685016. PubMed DOI PMC

Saleh S, Frey R, Becker C, et al. Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with or without food. Pulm Circ. 2016;6(Suppl 1):S66–S74. doi: 10.1086/685020. PubMed DOI PMC

European Medicines Agency, Evaluation of Medicines for Human Use, CPMP. Guideline on the investigation of Drug Interactions. CPMP/EWP/560/95 Rev. 1. London: 2012.

US Food and Drug Administration, Center for Drug Evaluation and Research (CDER): Guidance for industry. Drug Interaction Studies—Study design, data analysis, implications for dosing, and labeling recommendations, Rockville MD: February 2012.

OPSUMIT [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US, Inc. 2018. https://opsumit.com/opsumit-prescribing-information.pdf. Accessed 04 Feb 2019.

Polli JW, Hussey E, Bush M, et al. Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. Xenobiotica. 2013;43(6):498–508. doi: 10.3109/00498254.2012.739719. PubMed DOI

Becker C, Frey R, Hesse C, et al. Absorption of riociguat (BAY 63-2521): bioavailability, food effects, and dose proportionality. Pulm Circ. 2016;6(Suppl 1):S27–S34. doi: 10.1086/685018. PubMed DOI PMC

Issac M, Dingemanse J, Sidharta PN. Pharmacokinetics of macitentan in patients with pulmonary arterial hypertension and comparison with healthy subjects. J Clin Pharmacol. 2017;57(8):997–1004. doi: 10.1002/jcph.888. PubMed DOI